Alida Biosciences

Focus: Alida Biosciences is a San Diego-based biotech company specializing in epigenetic analysis tools for rare disease applications. The company operates in the pre-revenue or early-stage biotech segment with a focus on precision diagnostic and therapeutic development.

Rare Diseases

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Open Jobs

About Alida Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Alida Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Recent News · Alida Biosciences(3)

NewsFDA

Mar 18, 2026

FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development

The U.S. Food and Drug Administration today issued draft guidance intended to help drug developers validate new approach methodologies (NAMs) to be used instead of animal testing in drug development, and to bring safe, effective drugs to market sooner based on human-centric data.

Help build intelligence for Alida Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge epigenetics platform technology with demonstrated industry validation through STORM Therapeutics collaboration (announced Jan 2026)
Rare disease focus offers potential for expedited regulatory pathways and meaningful patient impact in underserved areas
Early-stage position provides hands-on ownership of research and development with equity upside potential

Watch Out For

Zero active job postings and unclear employee count suggest minimal current hiring or possible pre-launch operational mode
No clinical programs, revenue, or published pipeline data creates visibility risk around company stage and capital runway
Limited public disclosure on funding, financials, or development timeline raises questions about resource availability and execution capability

Generated by Claude from Alida Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.